REGENXBIO, which is developing gene therapies for rare diseases and licensing out gene delivery technology, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The Rockville, MD-based company, which was founded in 2008 and booked $4 million in revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol RGNX. REGENXBIO initially filed confidentially on July 1, 2015. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
